Found: 2
Select item for more details and to access through your institution.
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
- Published in:
- Hematological Oncology, 2023, v. 41, p. 239, doi. 10.1002/hon.3163_156
- By:
- Publication type:
- Article
UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.50_2880
- By:
- Publication type:
- Article